Informace o publikaci

Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience

Autoři	ZEMANOVA Milada PIRKER Robert PETRUZELKA Lubos ZBOŽÍNKOVÁ Zuzana JOVANOVIC Dragana RAJER Mirjana BOGOS Krisztina PURKALNE Gunta CERIMAN Vesna CHAUDHARY Subhash RICHTER Igor KUFA Jiri JAKUBÍKOVÁ Lenka ZEMAITIS Marius CERNOVSKA Marketa KOUBKOVA Leona VILASOVA Zdenka DIECKMANN Karin FARKAS Attila SPASIC Jelena FRÖHLICH Kateřina TIEFENBACHER Andreas HOLLOSI Virag KULTAN Juraj KOLAROVA Iveta VOTRUBA Jiri
Rok publikování	2020
Druh	Článek v odborném periodiku
Časopis / Zdroj	RADIOLOGY AND ONCOLOGY
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://www.radioloncol.com/index.php/ro/article/view/3384
Doi	http://dx.doi.org/10.2478/raon-2020-0026
Klíčová slova	diagnostic procedures; multimodality treatment; non-small-cell lung cancer; stage III
Popis	Background. Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the realworld setting in Central European countries to define areas for improvements. Patients and methods. This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results. Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions. The real-world study demonstrated a broad heterogeneity in the management of stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.